MedTrace Logo

Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

NCT01089101 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 217

Last updated 2026-05-13

No results posted yet for this study

Summary

This phase I/II trial studies the side effects and the best dose of selumetinib and how well it works in treating or re-treating young patients with low grade glioma that has come back (recurrent) or does not respond to treatment (refractory). Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions

  • Low Grade Glioma
  • Recurrent Childhood Pilocytic Astrocytoma
  • Recurrent Neurofibromatosis Type 1
  • Recurrent Visual Pathway Glioma
  • Refractory Neurofibromatosis Type 1
  • Refractory Visual Pathway Glioma

Interventions

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

DRUG

Selumetinib

Given PO

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Jason R Fangusaro · Pediatric Brain Tumor Consortium

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-07
Primary Completion
2026-01-17
Completion
2027-03-18

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01089101 on ClinicalTrials.gov